Troiano et al. demonstrated that the overexpression of M2-like CD163+ TAMs in patients with HNSCC is associated with poor clinical prognosis in terms of both overall survival (OS) and progression-free survival (PFS) [51], and a previous study indicated that CD163+ TAMs can serve as prognostic indicators in OSCC [52]. The gene discussed is CD163; the disease is head and neck squamous cell carcinoma.